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once annually during the study period of 2000–2005, were >=30
years old, and did not have a diagnosis of pregnancy or cancer.
Hospitalization attributable to diabetes was deﬁned as admis-
sions due to diabetes, diabetic complications, or cardiovascular
diseases. Cox-proportional hazard model was developed to
determine signiﬁcant factors for hospitalizations after adjusting
for the study variables. Two-part model (First part: logistic
regression and second part: generalized linear model with log
link function) was utilized to estimate mean length of stay.
RESULTS: A total of 7952 patients with type 2 diabetes were
identiﬁed with mean age of 57.4. Approximately 5.4% of them
were hospitalized due to diabetes. Type 2 diabetes patients were
more likely to be admitted if they were older than 65 years
(relative risk (RR) = 1.36; 95% conﬁdence interval
(95%CI) = 1.09–1.71), took both insulin and oral antidiabetic
medications (RR = 4.31; 95% CI = 3.30–5.63) compared to
patients without diabetic treatment, or had frequent physician
ofﬁce visits (RR = 2.06; 95% CI = 1.53–2.76). Overall, patients
stayed at the hospital on average of 2.23  0.08 days. CON-
CLUSION: Type 2 diabetes patients who took both insulin and
oral antidiabetic medications due to poor glucose control were
more likely to be admitted to hospital. It is recommended that
aggressive early intervention for controlling blood glucose and
improving compliance with diabetes treatment may prevent hos-
pitalizations related with diabetes.
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OBJECTIVE: Physician pay-for-performance are gaining
momentum as an approach to improve health care quality in the
United States. The objective of this study was to show the ben-
eﬁcial effects of physician incentive programs for the treatment of
diabetic patients as well as the potential for cost saving.
METHODS: Administrative claims data from a large regional
health plan were used through the 2004–2005 time-frame. Dia-
betic patients age 18–75 with private health insurance coverage
were included in the analysis. Multivariate Poisson regression
was used to model the likelihood of diabetes-related hospitaliza-
tions between patients who were being treated by a physician
participating in the incentive program and those that were not.
Likewise, cost savings associated with diabetic patients treated
by physicians participating in the incentive program was also
computed. RESULTS: Over a two year period, patients in the
P4P program showed a lower combined predicted number of
hospitalizations (0.31) than that of patients not in a P4P program
(0.39). In addition, cost beneﬁt analysis using decision tree mod-
eling showed the costs of the P4P program was entirely covered
by the reduction in cost resulting from decreased hospitalization
rates. With the incentive program, the health plan saved approxi-
mately $24 per adult diabetic and a total cost savings of
$675,000. Sensitivity analysis shows that the higher quality of
care resulting from the incentive based programs directly beneﬁts
outcomes of diabetes patients with an added beneﬁt of reducing
program cost. CONCLUSION: The cost savings associated with
physician pay-for-performance programs depend highly on the
effectiveness of the program to improve delivery of quality care.
Physician incentive programs have the potential to improve
patient outcomes as well as lead to economic beneﬁts for payers.
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OBJECTIVE: To develop a model to predict the probability of
diabetes patients having inpatient hospitalization in the follow-
ing year. METHODS: A retrospective cohort study was con-
ducted based on a population of 322 type II diabetes patients age
>=19 and enrolled in a Medicaid managed care plan from the
year 2003 to 2005. Models were developed by using medical/
pharmacy utilization data to predict the probability of having the
following events in the next year: (1) whether the patient had any
inpatient hospitalization, (2) whether the patient had any micro/
macro vascular inpatient hospitalization, (3) whether the patient
had any metabolic related inpatient hospitalization and (4)
whether the patient had any infectious inpatient hospitalization.
Main predictors of interests are diabetes compliance and the use
of statin. Covariates include diabetes treatment pattern, age, sex,
co-morbidities among other variables. Logistic model is used to
conduct the analysis. RESULTS: The study population was 74%
female with an average age of 49.2 (S.D = 8.4). Non-adherence
of diabetes drug (odds ratio = 1.57, 95% CI: 1.09–2.24), use of
statin (odds ratio = 0.58, 95% CI: 0.39–0.85), and previous
inpatient history (odds ratio = 3.50, 95% CI: 2.42–5.07) were
signiﬁcant in predicting any inpatient hospitalization. Non-
adherence of diabetes drugs was not a signiﬁcant predictor for
micro/macro vascular events (odds ratio = 0.74, 95% CI: 0.33–
1.67), but it was associated with signiﬁcantly increased prob-
abilities of having metabolic events (odds ratio = 1.58, 95% CI:
1.03–2.43) and infectious events (odds ratio = 2.70, 95% CI:
1.10–6.66). The use of statin was signiﬁcant only for predicting
metabolic events (odds ratio = 0.49, 95% CI: 0.32–0.77). It was
not signiﬁcant for predicting vascular events (odds ratio = 0.98,
95% CI: 0.45–2.15) and infectious events (odds ratio = 1.40,
95% CI: 0.49–3.72). CONCLUSION: The modeling results
show that improving compliance of diabetes drug and encourag-
ing the use of statin could be associated with reducing inpatient
hospitalizations in a short period of time.
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OBJECTIVE: To assess the budgetary impact of adding the ﬁxed-
dose pioglitazone plus glimepiride to a managed care formulary
plan over a three-year period (2006–2008). METHODS: This
model is an Excel-based spreadsheet which assumes a hypotheti-
cal scenario wherein a plan comprising one million covered lives
assesses the ﬁnancial impact of pioglitazone plus glimepiride to
formulary. The prevalence of type 2 diabetes is assumed to be
4.64% or approximately 46,400 members. Existing oral anti-
diabetic (OAD) agents on the formulary include TZDs (pioglita-
zone, rosiglitazone, TZD combinations with metformin, &
rosiglitazone plus glimepiride), sulfonylureas (glipizide, gly-
buride, glimeperide), metformin, & a DPP4 inhibitor (sitaglip-
tin). Costs for these agents were based on WAC (2006). Market
shares were based on internal market research and IMS data.
Metrics of budgetary impact are reported in terms of annual
treatment costs & per member per month (PMPM) costs. These
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